| Prev Close | 155.93 |
| Open | 156.88 |
| Day Low/High | 156.25 / 160.08 |
| 52 Wk Low/High | 145.86 / 179.92 |
| Volume | 4.86M |
Johnson & Johnson (JNJ)
159.47
3.50
2.30
NYSE
| Exchange | NYSE |
| Shares Outstanding | 2632.60B |
| Market Cap | 420.56B |
| P/E Ratio | 28.74 |
| Div & Yield | N.A. (N.A) |
Latest News
Omicron, Black Friday, Jobs Week, Cybersecurity, Trading Zscaler
I wouldn't expect a lot in the way of economic shutdowns, at least not unless clear evidence presents that people are getting sicker from Omicron.
Fingers Crossed for a Small-Cap Revenge Rally in 2022
The lingering effects of the pandemic have been hard on smaller biotech and healthcare stocks, but the worm could turn next year.
Heads Up on JNJ
A heads up. Johnson & Johnson is ex-dividend $1.06/share today.
Breaking Up - for Johnson & Johnson - Is Not Hard to Do
They say that breaking up is hard to do Now I know I know that it's true Don't say that this is the end Instead of breaking up I wish that we were making up again - Neil Sedaka, Breaking Up Is Hard To Do While many embrace the speculative orgy of...
New Buy (and Short) 'Levels'
* My revised levels I don't want there to be any ambiguity about the size of my positions, or about my buy and short levels, as I strive for as much transparency as possible. This column is a continued commitment towards that sort of disclosure. "Wh...
GE and JNJ Aren't the Only Aging Companies That Could Benefit From a Breakup
These moves could serve as a benchmark for other bigger, older, and perhaps bloated companies. Here are some candidates.
Johnson & Johnson Joins the Breakup Club: Here's How to Play It
J&J will be separating into two distinct firms, but not right away.
AT&T Should Break Itself Up (Further)!
This morning Johnson & Johnson joined a long and growing list, including a recently announced disaggregation, of companies that are breaking into parts. AT&T is already disaggregating - with the Warner/Discovery deal - and perhaps should go even fu...
Are Pandemic-Driven Panic Buying Stocks Suddenly Passe?
There is a lingering apprehension that the moment has passed for many of these names.
Black Monday Recollections, Bitcoin ETF Launch, Fed Numbers, FDA, Disney's Dip
While cryptocurrencies are indeed an asset class, and they are divisible, they do not serve as a medium of exchange, and remain unproven as a store of value.
Here's How Johnson & Johnson Stock Looks Ahead of Earnings
All eyes will be on JNJ as it releases its numbers Tuesday.
Super Thursday, Filling Gaps, Crypto Regulator Talk, Amazing Alcoa, AMD Love
Plus, an FDA advisory panel gives a unanimous boost to a Moderna booster shot and Boeing slumps on a negative news report.
Booster Club
As you mark your October calendar for what I shared earlier, also keep your eyes on Oct. 14-15. Those are the days a panel of FDA advisors will meet to discuss whether to recommend booster shots of Covid-19 vaccines from Moderna and Johnson & Johnso...
Jim Cramer: I'll Put My Money With 'Boring but Lucrative' Any Day
Let's look at that recent downgrade of 'dull' Morgan Stanley and see why exciting is best left for the stadiums and amusement parks -- and not stocks.
Clinically Speaking: 6 Stocks Behind the Scenes at Drug Trials
Investors are increasingly looking to the companies involved in clinical trials. Here are six favorite names in this space.
Fed Speaks, Taper Timeline, Dot Fantasy, Evergrande, DC Circus, Booster Stocks
It was as if markets heard what they wanted to hear, when it was actually much more simple: markets heard exactly what they had anticipated.
Jim Cramer: Not Only Did Apple Win But Epic Games Lost Big
How come this decision was so opaque to so many?
Figuring Out How to Play the S&P 500 Pullback and Johnson & Johnson
It's time to turn to the chart to determine whether the pullback is an opportunity to buy or if it is something more.
An Options Play on J&J
Johnson & Johnson's selloff seems to be losing some steam here.
Market Fatigue, Treasuries Death Cross, Meme Memo, Taiwan Semi, Oh What a Night
I could be wrong, but as far as I can tell, nobody else is telling the story about the sudden movement in these yields.
Comirnaty, Semiconductor-Palooza, Infrastructure Snag, Trading Cybersecurity
The fiscal football remains a greater threat this week than anything Fed Chair Jerome Powell says on Zoom this Friday.
Henri, Fiscal and Monetary Uncertainty, Vaccine Update, Trading Nvidia and AMD
Investors come into this week with 'all eyes' on the Kansas City Fed's economic symposium come week's end.
Pfizer's Charts Suggest a Strong Rally Ahead
Here are our latest price targets.
Look No Further Than AbbVie If You Need a Defensive/Dividend Type Name
AbbVie has been a Sarge fave for a long time. Sarge has been rewarded for trusting this firm's management when they acquired Allergan as a means toward replacing expected reductions in cash flows moving forward as the firm's patents for winder dru...
Jim Cramer: The Drug Cos. Are at Full Strength
We're seeing a group move in pharma right now, so let's sort it out, pill by pill.
Resilience? Stagflation Signs, Nvidia Action, Fed Hawks on Deck, Booster Rockets
A wall of liquidity seems to absorb every dip. But there are also enough reasons to be ever vigilant.
Jim Cramer: To Every Market Sector, Turn, Turn, Turn
To the melody of the Byrds' famed song, I want you to know: There's a time to buy the industrials, a time to sell the banks; a time to bid for health cares, a time to dump the techs. ...
